United Therapeutics CEO logs 10b5-1 option exercise and share sales
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
United Therapeutics (UTHR) reported insider activity by its Chairperson & CEO. Under a pre-arranged Rule 10b5-1 plan, the executive exercised 8,000 stock options at $120.26 on 10/21–10/22/2025 and sold 8,000 shares in related transactions at weighted average prices ranging from $420.00 to $432.20. The plan continues until the earlier of exhaustion of a tranche of 294,000 options expiring 03/15/2026 or 12/31/2025.
After these trades, direct holdings were 130 shares. Indirect holdings were disclosed as 166 shares by spouse and trust positions of 324,518; 258,117; 45,596; and 15,962 shares. Remaining stock options beneficially owned were 162,000 with an expiration of 03/15/2026.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Seller: 8,000 shares ($3,399,650)
Net Sell
16 txns
Insider
ROTHBLATT MARTINE A
Role
Chairperson & CEO
Sold
8,000 shs ($3.40M)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option | 4,000 | $0.00 | -- |
| Exercise | Common Stock | 4,000 | $120.26 | $481K |
| Sale | Common Stock | 634 | $420.4701 | $267K |
| Sale | Common Stock | 2,200 | $422.1505 | $929K |
| Sale | Common Stock | 1,166 | $423.0686 | $493K |
| Exercise | Stock Option | 4,000 | $0.00 | -- |
| Exercise | Common Stock | 4,000 | $120.26 | $481K |
| Sale | Common Stock | 1,088 | $425.3831 | $463K |
| Sale | Common Stock | 1,412 | $426.1843 | $602K |
| Sale | Common Stock | 1,000 | $430.3536 | $430K |
| Sale | Common Stock | 500 | $432.20 | $216K |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Stock Option — 162,000 shares (Direct);
Common Stock — 4,130 shares (Direct);
Common Stock — 166 shares (Indirect, by Spouse)
Footnotes (1)
- This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person on May 2, 2025. This plan will continue until the earlier of: (a) exhaustion of a tranche of 294,000 stock options that expire March 15, 2026; or (b) December 31, 2025. Shares held in family trusts as to which the Reporting Person's spouse shares investment power and the Reporting Person and/or immediate family members are beneficiaries. Shares held in family trusts as to which the Reporting Person is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke. This transaction was executed in multiple trades at prices ranging from $424.75 to $425.54. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $425.94 to $426.49. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $430.14 to $430.42. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $420.00 to $420.715. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $421.75 to $422.54. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $423.06 to $423.16. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries. Shares held in family trusts as to which the Reporting Person's spouse is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke.
FAQ
What insider transaction did UTHR's CEO report on Form 4?
The executive exercised 8,000 stock options at $120.26 and sold 8,000 shares on 10/21–10/22/2025 under a Rule 10b5-1 plan.
What indirect UTHR holdings were disclosed for the CEO?
Indirect holdings include 166 shares by spouse and trusts holding 324,518; 258,117; 45,596; and 15,962 shares.
How many UTHR stock options remain beneficially owned by the CEO?
162,000 stock options remain beneficially owned, with an expiration date of 03/15/2026.
What are the key terms of the CEO’s 10b5-1 trading plan?
The plan runs until the earlier of the exhaustion of a 294,000-option tranche expiring 03/15/2026 or 12/31/2025.